AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16442368
Drug: rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin 10 mg and 20 mg
Trial: 8277150
Drug: Fluoxetine, 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine, 60 mg daily
Trial: 24599529
Drug: AS02V with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS02V with 10 or 30 μg PhtD-dPly
Trial: 24599529
Drug: Alum with
RxNorm normalized name: alum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alum with 10 or 30 μg PhtD-dPly
Trial: 24176494
Drug: 23-valent polysaccharide
RxNorm normalized name: pneumococcal 23-valent polysaccharide vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23-valent polysaccharide pneumococcal vaccine (23PPV)
Trial: 22103985
Drug: Isokinetic training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isokinetic training programme (3 times weekly, starting at 60% of average peak torque, increasing from 1 set to 10 sets over sessions)
Trial: 18977178
Drug: Control patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control patch (3.2 microg/cm² [0.04% capsaicin])
Trial: 17124437
Drug: Intratympanic gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratympanic gentamicin (40 mg/ml, 0.7 ml; n=24)
Trial: 17124437
Drug: Intratympanic dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intratympanic dexamethasone (4 mg/ml, 0.7 ml; n=21)
Trial: 12208583
Drug: Bosentan (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan (125 mg twice a day)
Trial: 3246246
Drug: Nicardipine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (0.2 mg over 10 min)
Trial: 27259463
Drug: HDF‐IPIS with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDF‐IPIS with [Na+] of 240 mmol L-1
Trial: 27259463
Drug: HDF‐IPIS with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDF‐IPIS with [Na+] of 500 mmol L-1
Trial: 14728641
Drug: Home treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home treatment from a geriatric home hospitalization service (GHHS)
Trial: 14728641
Drug: General medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General medical ward treatment (GMW)
Trial: 11527658
Drug: Fenofibrate plus
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fenofibrate plus folic acid (10 mg every other day)
Trial: 8381646
Drug: Intravenous ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ganciclovir for 14 to 21 days (for primary TI‐CMV disease)
Trial: 2893240
Drug: Flumazenil (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (0.2 to 1.0 mg in anaesthesiology; 0.1 to 2.0 mg in intensive care)
Trial: 2893240
Drug: Flumazenil (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (single dose)
Trial: 2893240
Drug: Flumazenil (repeated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (repeated low intravenous doses or infusion at 0.1 mg/hour)
Trial: 31177714
Drug: Comprehensive rehabilitation
RxNorm normalized name: Easy Care First Aid Kit - Comprehensive KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive rehabilitation treatment of individualized exercise program
Trial: 21596324
Drug: Pravastatin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin treatment (20 mg/day, n = 40)
Trial: 21596324
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (n = 40)
Trial: 10637238
Drug: Chemotherapy (CAF:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CAF: cyclophosphamide, doxorubicin, and fluorouracil)
Trial: 10637238
Drug: Chemohormonal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemohormonal therapy (CAFTH: CAF plus tamoxifen and Halotestin)
Trial: 10637238
Drug: Chemohormonal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemohormonal therapy (CAFTH)
Trial: 10637238
Drug: Chemotherapy (CAF)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CAF)
Trial: 29215955
Drug: Trifluridine/tipiracil (TAS-102),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trifluridine/tipiracil (TAS-102), administered twice per day orally; 5 days on and 2 days off for 2 weeks, followed by 14 days off per cycle.
Trial: 27681394
Drug: multi‐herbal mouth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multi‐herbal mouth rinse, 15 ml twice a day
Trial: 27681394
Drug: 0.2% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% chlorhexidine mouth rinse, 15 ml twice a day
Trial: 27681394
Drug: essential oil
RxNorm normalized name: Essential oil
DrugBank: Rosemary oil (DB14689)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: essential oil mouth rinse, 15 ml twice a day
Trial: 27681394
Drug: 0.2% sodium
RxNorm normalized name: Dextrose 5% and 0.2% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% sodium fluoride mouth rinse, twice a day
Trial: 24131637
Drug: Tacrolimus triple
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus triple therapy (TT) - daily tacrolimus (0.1 mg/kg divided dose), azathioprine (1 mg/kg), and prednisolone (20 mg)
Trial: 16623815
Drug: Tacrolimus monotherapy
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus monotherapy (MT)
Trial: 23006660
Drug: Sucralfate (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (6 g twice a day for 4 weeks)
Trial: 15006216
Drug: Nurse-run telephone
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-run telephone self-management programme including six weekly mailings of OA health education modules, a relaxation audio-tape, and six weekly 45 min follow-up telephone sessions.
Trial: 11557168
Drug: d-amphetamine (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-amphetamine (0.25 mg/kg) administered on days 1, 3, and 5 (AAA)
Trial: 11557168
Drug: d-amphetamine (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-amphetamine (0.25 mg/kg) administered on day 5 after placebo on days 1 and 3 (PPA)
Trial: 11557168
Drug: placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo administered on days 1, 3, and 5 (PPP)
Trial: 7908800
Drug: Low-dose diazepam
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose diazepam (ED)
Trial: 30825962
Drug: Concurrent FSRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent FSRT and alisertib (20 mg, 30 mg, 40 mg, and 50 mg BID)
Trial: 30825962
Drug: Concurrent FSRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent FSRT and alisertib
Trial: 30825962
Drug: Concurrent FSRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent FSRT and alisertib (50 mg cohort)
Trial: 17434884
Drug: Daily low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily low-dose leuprolide injections (0.5 mg/day)
Trial: 17434884
Drug: Single-dose leuprolide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose leuprolide injection (1.88 mg)
Trial: 12202657
Drug: Paclitaxel 200
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 200 mg/m² plus carboplatin AUC 6 (group A)
Trial: 12202657
Drug: Paclitaxel 200
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 200 mg/m² plus gemcitabine 1,000 mg/m² (group B)
Trial: 8942329
Drug: Propofol (20-h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (20-h infusion at 0.1 ml kg-1 h-1)
Trial: 8942329
Drug: Intralipid (10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid (10% as placebo, 20-h infusion at 0.1 ml kg-1 h-1)
Trial: 2017470
Drug: Dietary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary treatment with education to 'internal spontaneity', resulting in a 21% decrease in energy intake (p < 0.05) and increased fruit and nonstarchy vegetable intake.
Trial: 2017470
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no dietary treatment).
Trial: 7081116
Drug: Test diet
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test diet (49.67 mg tin daily)
Trial: 7081116
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet (0.11 mg tin daily)
Trial: 23725348
Drug: 2800 BAU
RxNorm normalized name: Grastek 2800 BAU Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2800 BAU Timothy grass AIT (oral lyophilisate, Phleum pratense, 75,000 SQ-T, containing approximately 15 μg of Phl p 5)
Trial: 19521932
Drug: Intracoronary administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary administration of 20 ml of bone marrow cells (BMC) to the infarct-related artery (IRA) after primary PCI
Trial: 19521932
Drug: Bare metal
RxNorm normalized name: menthone 1,2-glycerol ketal, (-)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bare metal stenting of IRA without BMC administration
Trial: 15385375
Drug: Large-dose calcium
RxNorm normalized name: Bos taurus large intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large-dose calcium (15 mmol/h)
Trial: 15385375
Drug: Small-dose calcium
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small-dose calcium (5 mmol/h)
Trial: 396659
Drug: Pirenzepine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (150 mg daily)
Trial: 20208358
Drug: Placebo (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0 g)
Trial: 26452342
Drug: Oral switch
RxNorm normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral switch therapy (OST)
Trial: 26452342
Drug: Intravenous standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous standard therapy (IST)
Trial: 20299956
Drug: Conjugated pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated pneumococcal vaccine (CPV) + polysaccharide pneumococcal vaccine (PPV)
Trial: 20299956
Drug: Polysaccharide pneumococcal
RxNorm normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polysaccharide pneumococcal vaccine (PPV) alone
Trial: 19271025
Drug: Trimetazidine (TMZ)
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (TMZ) 60 mg/day divided into three doses for 6 months
Trial: 12922095
Drug: 7VPnC plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7VPnC plus DTaP‐IPV‐Hib vaccines
Trial: 12922095
Drug: DTaP‐IPV‐Hib vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP‐IPV‐Hib vaccine plus 7VPnC catch-up vaccination
Trial: 11095261
Drug: BCL2 antisense
RxNorm normalized name: Exon 53 specific antisense morpholino oligonucleotide
DrugBank: Viltolarsen (DB15005)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: BCL2 antisense oligonucleotides (augmerosen) plus standard dacarbazine treatment
Trial: 8797612
Drug: 15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg BAY x 1351
Trial: 8797612
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg BAY x 1351
Trial: 30729631
Drug: Lecture (L)
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lecture (L)
Trial: 29648580
Drug: Bevacizumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (10 mg/kg for 14 days) plus hypofractionated radiotherapy (40 Gy in 15 fractions)
Trial: 27189086
Drug: Daily prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily prednisone (1-2 mg/kg/day for 2-4 weeks with subsequent dose reduction)
Trial: 27189086
Drug: Pulsed dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pulsed dexamethasone (0.6 mg/kg/day, days 1-4 for six 3-week cycles)
Trial: 28450193
Drug: Daily prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily prednisone
Trial: 20592647
Drug: R-methamphetamine (R-MA)
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-methamphetamine (R-MA) 0 mg
Trial: 20592647
Drug: R-methamphetamine (R-MA)
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-methamphetamine (R-MA) 1 mg
Trial: 20592647
Drug: R-methamphetamine (R-MA)
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-methamphetamine (R-MA) 2.5 mg
Trial: 20592647
Drug: R-methamphetamine (R-MA)
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-methamphetamine (R-MA) 5 mg
Trial: 20592647
Drug: R-methamphetamine (R-MA)
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-methamphetamine (R-MA) 10 mg
Trial: 20592647
Drug: R-methamphetamine (R-MA-d3)
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-methamphetamine (R-MA-d3) 2.5 mg (IV)
Trial: 17296648
Drug: Esomeprazole, 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole, 40 mg bid
Trial: 9354200
Drug: O 20
RxNorm normalized name: ABO 201
DrugBank: ABO-201 (DB17951)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O 20 mg b.d. + C 500 mg b.d. + A 1 g b.d. for 7 days (OAC)
Trial: 9354200
Drug: O 20
RxNorm normalized name: ABO 201
DrugBank: ABO-201 (DB17951)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O 20 mg b.d. + C 250 mg b.d. + M 500 mg b.d. for 7 days (MOC)
Trial: 9354200
Drug: C 250
RxNorm normalized name: Cinobac 250mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C 250 mg b.d. + M 500 mg b.d. for 7 days (CM)
Trial: 9354200
Drug: A 1
RxNorm normalized name: ACA 125
DrugBank: ACA 125 (DB05489)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 1 g b.d. + clarithromycin (C) 500 mg b.d. for 7 days (AC)
Trial: 9354200
Drug: O 20
RxNorm normalized name: ABO 201
DrugBank: ABO-201 (DB17951)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O 20 mg b.d. + amoxycillin (A) 1 g t.d.s. for 14 days (OA)
Trial: 3333018
Drug: Calcium infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium infusions
Trial: 24793366
Drug: Vaccine (succinylnorcocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine (succinylnorcocaine conjugated to cholera toxin B protein)
Trial: 24793366
Drug: High IgG
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High IgG group (≥42 μg/mL)
Trial: 24793366
Drug: Vaccine and
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine and Placebo
Trial: 23025511
Drug: OC000459 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC000459 200 mg bid
Trial: 7803209
Drug: Octreotide acetate
RxNorm normalized name: Octreotide Acetate
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Octreotide acetate 0.1 mg s.c. 45 minutes before ERCP, followed by another dose 6 hours later.
Trial: 28154996
Drug: Nanostructured calcium‐incorporated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nanostructured calcium‐incorporated (NCI) implants
Trial: 27861190
Drug: Machined (MA)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machined (MA) implants
Trial: 28154996
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between NCI and MA implants
Trial: 25257978
Drug: Bupropion and
RxNorm normalized name: bupropion and naltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion and cognitive behavioral therapy
Trial: 25771851
Drug: Rosuvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (10 mg/day)
Trial: 23442255
Drug: Sevelamer hydrochloride
RxNorm normalized name: Sevelamer Hydrochloride
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevelamer hydrochloride (2,400 mg/day)
Trial: 23885048
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (500 mg twice daily)
Trial: 20688474
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (1000 IU twice daily)
Trial: 19748402
Drug: Ischemic Compression
RxNorm normalized name: oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ischemic Compression (IC) treatment for MTrPs
Trial: 19748402
Drug: Ultrasound (US)
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound (US) treatment for MTrPs
Trial: 10945088
Drug: Antidepressant trials
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant trials with improved blindness procedures
Trial: 9127371
Drug: 2 million
RxNorm normalized name: Carticel 12 million cells/vial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 million U penicillin G every 4 hours
Trial: 1550533
Drug: Buccal scopolamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal scopolamine
Trial: 3299565
Drug: Ambroxol 120
RxNorm normalized name: AMBROXOL
DrugBank: Ambroxol (DB06742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol 120 mg daily
Trial: 3299565
Drug: Ambroxol 60
RxNorm normalized name: ambroxol 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol 60 mg daily
Trial: 22240792
Drug: FOLFIRI plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI plus bevacizumab (Bev) 5 mg kg(‐1) every 2 weeks (Arm-A)
Trial: 22240792
Drug: CAPIRI plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAPIRI plus bevacizumab (Bev) 7.5 mg kg(‐1) every 3 weeks (Arm-B)
Trial: 18691392
Drug: Pedometer plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pedometer plus theory-based intervention (with 20% monthly increase target)
Trial: 18691392
Drug: Pedometer plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pedometer plus theory-based intervention (with 10% and 15% monthly increase targets)
Trial: 15850917
Drug: Tamsulosin (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin (0.8 mg, orally once a day)
Trial: 8950881
Drug: MNrgp120 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MNrgp120 vaccine
Trial: 7043385
Drug: Testosterone enanthate,
RxNorm normalized name: Testosterone Enanthate, enanthate 200 mg/mL intramuscular solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate, 200 mg administered intramuscularly four times at three-week intervals
Trial: 30714427
Drug: Intrauterine infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrauterine infusion of 0.5 ml platelet-rich plasma (PRP) 48 hours before blastocyst transfer
Trial: 31097515
Drug: CPAP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP treatment in non-dipper patients
Trial: 31097515
Drug: CPAP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP treatment in dipper patients
Trial: 25359163
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin D3 (4000 IU/d)
Trial: 25359163
Drug: Low-dose vitamin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose vitamin D3 (400 IU/d)
Trial: 10731269
Drug: Intracoronary nicardipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary nicardipine (200 mcg)
Trial: 16890144
Drug: High sodium
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High sodium diet (HS) response to Ang II infusion
Trial: 16890144
Drug: Low sodium
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low sodium diet (LS) response to Ang II infusion
Trial: 8227112
Drug: Oral mesoglycan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral mesoglycan (200 mg/day)
Trial: 7926242
Drug: Goserelin depot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin depot therapy for 2 months
Trial: 2911851
Drug: Therapeutic drug
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic drug monitoring program
Trial: 3652932
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of the therapeutic drug monitoring program
Trial: 2911851
Drug: Reinstitution of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reinstitution of the therapeutic drug monitoring program